Regeneron Pharmaceuticals

Immunotherapy
#Cancer immunotherapy #Cervical cancer #National Institute for Health and Care Excellence (NICE) #Regeneron Pharmaceuticals

NICE recommends immunotherapy to treat cervical cancer 

The National Institute for Health and Care Excellence (NICE) has recommended cemiplimab for the treatment of advanced cervical cancer.  The immunotherapy, developed by biotechnology company Regeneron, has been recommended in England and Wales to treat recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy in adults.   This… Read More

#News #Regulatory

Non-small cell lung cancer
#Lung cancer #National Institute for Health and Care Excellence (NICE) #NHS #Non-small cell lung cancer (NSCLC) #Regeneron Pharmaceuticals

NICE recommends lung cancer combination therapy 

The National Institute for Health and Care Excellence (NICE) has recommended cemiplimab in combination with platinum-based chemotherapy to treat patients with non-small cell lung cancer (NSCLC).  Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, which was shown to block cancer cells from using the PD-1… Read More

#News #Regulatory

Gene therapy
#FDA #Gene therapy #Hearing Loss #Regeneron Pharmaceuticals

FDA approves first gene therapy for genetic hearing loss

The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Otarmeni (lunsotogene parvec-cwha), the first gene therapy and second new molecular entity approved under the FDA Commissioner’s National Priority Voucher programme.   Otarmeni is an adeno-associated virus vector-based gene therapy indicated for the treatment of paediatric and… Read More

#News #Regulatory #Trending News

#Collaboration #Radiopharmaceuticals #Regeneron Pharmaceuticals #Telix Pharmaceuticals

Regeneron & Telix collaborate on next-gen radiopharmaceuticals

Pharmaceutical companies Regeneron and Telix have announced a collaboration to develop and commercialise next generation radiopharmaceutical therapies. The collaboration will include multiple solid tumour targets from Regeneron’s portfolio of antibodies. The companies also aim to develop radio-diagnostics to support patient selection and treatment response assessment. The deal will see Telix… Read More

#Business & Investment #News

Cell and gene therapy
#Gene therapy #Genetics / genomics #Hearing Loss #Regeneron Pharmaceuticals

Gene therapy brings “new era” in the treatment of hearing loss

New gene therapy trial results have shown dramatic and sustained improvements in hearing and speech perception in children with profound genetic hearing loss.  The updated data for Regeneron Pharmaceuticals’ investigational gene therapy DB-OTO for profound genetic hearing loss due to variants of the otoferlin (OTOF) gene were… Read More

#News #Trending News

A child with a cochlear implant
#Gene therapy #Genetic diseases #Hearing Loss #Paediatrics #Regeneron Pharmaceuticals

Latest DB-OTO results confirm hearing improvements

Regeneron Pharmaceuticals has revealed updated data for the investigational gene therapy DB-OTO from the Phase I/II CHORD trial in 12 children who have profound genetic hearing loss due to variants of the otoferlin (OTOF) gene.   These include 72-week results showing speech and development progress… Read More

#Editor's Choice #News

Scotland flag
#Oncology #Phase III trial #Regeneron Pharmaceuticals #Scottish Medicines Consortium (SMC)

Scotland approval for cervical cancer therapy

The Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on the National Health Service (NHS) as a second-line monotherapy for adults with recurrent or metastatic cervical cancer.  It is approved in patients who have disease progression on or after platinum-based chemotherapy, irrespective of PD-L1 expression level or tumour… Read More

#News #Regulatory

EMA
#European Medicines Agency #Monoclonal antibodies #Paediatrics #Phase III trial #Regeneron Pharmaceuticals #Sanofi

EU Dupixent use extended to children with eosinophilic esophagitis

The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year old. The approval is limited to children aged one to 11 years who weigh at least 15kg and who are inadequately controlled by, intolerant to, or who are not candidates… Read More

#News #Regulatory

#Chronic obstructive pulmonary disease (COPD) #Monoclonal antibodies #Regeneron Pharmaceuticals #Sanofi

First biologic drug for COPD gets green light in US and China

Dupixent (dupilumab) has become the first biologic medicine for chronic obstructive pulmonary disease (COPD) in the US and China. Sanofi and Regeneron secured approvals from both the US Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) in the same week. It is approved for adults with… Read More

#News #Regulatory

Gene therapy
#Clinical trial #Gene therapy #Genetics / genomics #Hearing Loss #Paediatrics #Regeneron Pharmaceuticals

Gene therapy restores hearing in both ears

Five children who were born with congenital hearing loss can hear in both ears after taking part in a gene therapy trial at Fudan University in Shanghai, China. Within weeks of receiving the therapy, the children could locate the sources of sounds, and recognised speech in… Read More

#News

Treg cells
#Autoimmune disease #Collaboration #Partnership #Regeneron Pharmaceuticals #Sonoma Biotherapeutics #T cell activation

Companies combine efforts on Treg therapies for autoimmune diseases

Sonoma Biotherapeutics and Regeneron Pharmaceuticals have announced plans to collaborate on the discovery, development and commercialisation of novel regulatory T cell (Treg) therapies for autoimmune diseases. The collaboration will bring together Regeneron’s VelociSuite technologies for the discovery and characterisation of fully human antibodies and T cell… Read More

#News